Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Furuta

Showing results (231-240 of 232) with videos related to

Pageof 24
Sort By:
You have reached the last page of results.This site can display upto 232 results.
ESMO Gastrointestinal Oncology|February 6, 2026
WJOG18524G: a single-arm phase II study evaluating bemarituzumab combined with ramucirumab and paclitaxel in fibroblast growth factor receptor 2b (FGFR2b)-positive advanced gastric or gastroesophageal junction cancer (RAINBIRD)K Shimozaki, K Hirata, H Hayashi, et al.
ESMO Open|June 2, 2025
Lenvatinib for patients with previously treated advanced thymic carcinoma in real-world settingsK Takagi, G Saito, H Tanaka, et al.
Pageof 24

Showing results (231-240 of 232) with videos related to

Sort By:
Pageof 24
You have reached the last page of results.This site can display upto 232 results.
ESMO Gastrointestinal Oncology|February 6, 2026
WJOG18524G: a single-arm phase II study evaluating bemarituzumab combined with ramucirumab and paclitaxel in fibroblast growth factor receptor 2b (FGFR2b)-positive advanced gastric or gastroesophageal junction cancer (RAINBIRD)K Shimozaki, K Hirata, H Hayashi, et al.
ESMO Open|June 2, 2025
Lenvatinib for patients with previously treated advanced thymic carcinoma in real-world settingsK Takagi, G Saito, H Tanaka, et al.
Pageof 24